Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.65M of Stock
Japan Post Holdings Co. Ltd. sold 13,000 shares of Aflac Inc at $125.77 to $127.55 a share (average $126.89) in 3 transactions, worth $1.65M in total on Nov 10, 2026. Shares held after the trade: 50,121,329 (-0.0%).
Artelo Biosciences reported a net loss of $7.15 million for the nine months ended September 30, 2026, compared to $8.71 million in the prior year period. The company strengthened its balance sheet through equity financing, ending the quarter with $4.44 million in cash and cash equivalents, up from $0.6 million at the start of the year.
Imunon, Inc. reported a net loss of $10.8 million for the nine months ended September 30, 2026, compared to $10.3 million in the prior year period. The company's cash position decreased to $4.0 million from $8.8 million at year-end 2025, while total liabilities increased significantly due to the issuance of new notes payable.
Datacentrex, Inc. has prepared and furnished a formal investor presentation deck (Exhibit 99.1) regarding its operations and performance. Management intends to use these materials for upcoming presentations to investors and analysts.
PVH Corp. launched a global enterprise-wide initiative to accelerate strategic priorities and improve productivity, which includes reducing its global workforce by approximately 4%. The company expects to achieve at least $100 million in pre-tax cost reductions in fiscal 2027, increasing to $150 million annually starting in fiscal 2028.
Lester R. Brafman resigned as Chief Executive Officer of Cohen & Co Inc. effective November 10, 2026, and will serve as a Senior Advisor through November 30, 2026. Daniel G. Cohen, the company's Executive Chairman and former CEO, has been appointed to succeed him as Chief Executive Officer. The company stated the resignation was not due to any disagreement regarding operations, policies, or practices.
Chenghe Acquisition III Co. reported a net income of $2,633,792 for the nine months ended September 30, 2026, primarily driven by $3,235,400 in interest earned on cash held in the Trust Account. As a shell company, it has not yet generated operating revenue and is currently focused on identifying a target for its initial Business Combination.
Accelerant Holdings reported third quarter 2026 financial results, highlighted by a 27% year-over-year growth in Exchange Written Premium to $1.33 billion. Despite a GAAP net loss of $9.2 million, the company achieved adjusted net income of $38.2 million and reaffirmed its pending merger with Thoma Bravo, expected to close in the first half of 2027.
“The third quarter continued to show the strength of the Accelerant Risk Exchange, with Exchange Written Premium growing 27% year-over-year to $1.33 billion. We added 26 MGAs during the quarter, maintaining the upward momentum of our high-quality, specialty underwriting talent.”
Jeff Radke, Accelerant’s Chairman and Chief Executive Officer
“We delivered another quarter of disciplined growth, with operating revenue of $280.2 million and adjusted EBITDA of $71.3 million. Our fee-based businesses, which we define as consolidated results less the Underwriting segment, delivered $84.5 million of adjusted EBITDA, representing growth of 75% year over year.”
Linda S. Huber, Accelerant’s Chief Financial Officer
ProMIS Neurosciences Inc. has posted an updated corporate presentation to its website and filed it as an exhibit to its 8-K. The presentation provides a strategic overview of the company's development pipeline, including its PMN310 candidate for Alzheimer's disease and the PRECISE-AD Phase 1b clinical trial. The filing serves as a Regulation FD disclosure to provide investors with current information on the company's operations and clinical milestones.
Imunon, Inc. reported financial results for the third quarter ended September 30, 2026, and provided updates on its lead clinical candidate IMNN-001 for advanced ovarian cancer. The company highlighted its Phase 3 OVATION 3 study and a recent Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to support further development of IMNN-001.
“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer. The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation.”
Stacy R. Lindborg, Ph.D., President and Chief Executive Officer
Tonix Pharmaceuticals Holding CEO Seth Lederman Buys $20.3K of Stock
Seth Lederman, CEO, bought 5,000 shares of Tonix Pharmaceuticals Holding Corp. at $4.05 a share, worth $20.3K in total on Nov 11, 2026. Shares held after the trade: 16,005 (+45.4%).
SeaStar Medical reported Q3 2026 financial results, highlighted by a 247% increase in net revenue to $635,000 driven by adoption of its QUELIMMUNE therapy. The company also announced that its NEUTRALIZE-AKI pivotal clinical trial for adult patients is nearly 75% enrolled and it has submitted the first module of its PMA application to the FDA.
Term
Q3 2026
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications. And we continue to build momentum in educating the critical care pediatric health care community.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval.”
Phoenix Education Partners, Inc. declared a special cash dividend of $2.36 per share. The dividend is payable on December 4, 2026, to stockholders of record as of November 23, 2026.
CarParts.com announced several changes to its Board committees, including the appointment of Warren Phelps, III as Chair of the Nominating and Corporate Governance Committee. Tim Nauss was appointed to both the Audit and Nominating committees, while Nanxi Liu and Dr. Lisa Costa stepped down from their roles on the Nominating and Corporate Governance Committee.
CorMedix reported Q3 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, while maintaining its full-year 2026 revenue guidance. The company also highlighted its pending acquisition of Heron Therapeutics assets and a new $150 million term loan facility to support the transaction and operations.
Term
Q3 2026
“CorMedix will be entering 2027 with two meaningful potential growth drivers. First, our pending acquisition of the Heron assets adds four commercial products used in institutional settings of care and is expected to be immediately accretive to earnings and free cash flow upon closing.”
Joseph Todisco, Chairman & Chief Executive Officer
Skye Bioscience received a unanimous jury verdict in its favor following a retrial in the U.S. District Court for the Central District of California. The lawsuit, filed by a former employee, alleged whistleblower protection violations and retaliation related to events occurring between 2018 and 2019. The verdict clears the company of all claims, though the plaintiff retains the right to file post-trial motions or appeals.
MBX Biosciences Chairman, President and CEO Steven L. Hoerter Sells $268K of Stock
Steven L. Hoerter, Chairman, President and CEO, sold 4,893 shares of MBX Biosciences, Inc. at $54.82 a share, worth $268K in total on Nov 10, 2026. Shares held after the trade: 78,045 (-5.9%).
Iron Horse Acquisition II M&A Deal with Electra Vehicles, Inc.
Iron Horse Acquisition II Corp. (IRHO) and its merger target Electra Vehicles, Inc. (ELECTRA AI) announced a three-year partnership where Electra will serve as the Official Battery Intelligence Partner for Westbrook Racing at the E1 Miami GP. This update provides a strategic and marketing milestone for the companies as they work toward completing their previously announced business combination agreement dated April 21, 2026.
Charlotte's Web Holdings reported a net loss of $20.7 million for the nine months ended September 30, 2026, compared to $18.3 million in the prior year. Revenue decreased to $31.4 million from $36.6 million, while the company significantly improved its balance sheet by converting $50.8 million in convertible debentures into common shares.
Orion Group Holdings appointed retired U.S. Navy Rear Admiral Mark A. Handley to its Board of Directors, effective November 11, 2026. Mr. Handley, who previously held senior leadership roles at AECOM, will serve on the Audit, Compensation, and Nominating and Governance Committees. His appointment expands the company's board from six to seven directors.
Apollo Global Management's subsidiary, Athene Holding Ltd., is hosting a Fixed Income Investor call on November 12, 2026. The company has made a formal investor presentation available on its website to provide updates on business trends, new business origination, and its investment portfolio.
LASE Corp. reported a net loss of $8.57 million for the nine months ended September 30, 2026, compared to a loss of $8.11 million in the prior year period. Total assets increased significantly to $15.81 million from $9.45 million at year-end 2025, primarily driven by a substantial increase in current assets following multiple public offerings and warrant inducement exercises.
AllianceBernstein L.P. reported preliminary assets under management (AUM) of $901 billion as of October 31, 2026, a slight increase from $900 billion at the end of September. The growth was primarily driven by market appreciation, which was partially offset by net outflows in the Retail and Institutional channels.
Labcorp Holdings EVP, Pres of BLS, CMO & CSO Brian J. Caveney Sells $744K of Stock
Brian J. Caveney, EVP, Pres of BLS, CMO & CSO, sold 2,000 shares of Labcorp Holdings Inc. at $372.04 a share, worth $744K in total on Nov 10, 2026. Shares held after the trade: 34,562 (-5.5%).
First Watch Restaurant Group Investor Presentation
First Watch Restaurant Group is hosting its inaugural Investor Day in Boston to share its strategic growth vision and long-term financial targets through 2028. The company outlined a path to over 2,200 restaurants and expects to generate positive free cash flow beginning in 2027 to self-fund organic growth.
“Our strategy combines the strength of our leadership in Daytime Dining with substantial whitespace for restaurant growth and an increasingly powerful cash flow model. We see a clear path to more than 2,200 restaurants across the continental U.S. while, beginning next year, we expect our robust cash flow to self-fund organic growth and maintenance capital expenditures and accelerate free cash flow generation.”
Chris Tomasso, CEO and President of First Watch
“Our annual growth targets through 2028 strike an optimized balance between new unit growth and free cash flow. We are on track to open 62 systemwide restaurants in 2026 and approximately 55 in 2027, retaining flexibility on annual openings in the following years.”
Latch, Inc. (DOOR) reported Q3 2026 results featuring 18% software revenue growth and significant gross margin expansion to 55.2%. While total revenue declined 18.9% to $14.1 million due to lower hardware volume, the company improved its Adjusted EBITDA loss and launched its OpenDOOR developer platform.
Term
Q3 2026
“The third quarter results reflect our continued focus on driving profitability, highlighted by our improvement in gross margin. Our priorities are clear: strengthen our best-in-class integrated hardware and software platform, streamline operations, and build a more profitable and sustainable company.”
David Lillis, Chief Executive Officer
“We are leaning into what we do best and exiting non-core operations to focus our resources on higher-margin offerings. The restructuring plan we announced in August, which is expected to reduce annualized operating costs by $10 million to $12 million, is progressing as planned and should accelerate our path to profitability.”
Athene Holding Ltd. has made available a formal presentation titled 'Athene Fixed Income Investor Presentation November 2026' in connection with a fixed income investor call. The presentation was published on the company's investor relations website on November 12, 2026.
Hydrofarm Holdings Group Nasdaq/NYSE Compliance Notice
Hydrofarm Holdings Group, Inc. has regained compliance with Nasdaq's $2.5 million minimum stockholders’ equity requirement following a financial restructuring that eliminated $109 million in debt. The company remains subject to a Mandatory Panel Monitor for one year, during which any failure to satisfy the equity rule would result in an immediate delist notice without the opportunity to submit a new compliance plan.
Counterparty
Nasdaq
Term
through November 9, 2027
“We received notice from Nasdaq that we are in compliance on our stockholders’ equity, another milestone in our financial restructuring. With this confirmation, our organization is focused on profitable growth: our proprietary brands out of Eugene, the direct commercial sales channel that opened when the term loan was eliminated, and scaling logistics services under Project Agility. That’s where our 50th year starts.”
AllianceBernstein reported preliminary assets under management (AUM) of $901 billion as of October 31, 2026, a slight increase from $900 billion at the end of September. The growth was primarily driven by market appreciation, which was partially offset by net outflows in the Retail and Institutional channels.